Clinical Trials · NCT06297603
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 320
- Start date
- Mar 2024
- Locations
- 76 sites, 7 countries
- Primary endpoint
- Change from Baseline in Hemoglobin A1c (HbA1c) (%)